Potential targeted therapies for ovarian cancer beyond PARP inhibitors

This review aimed to investigate the clinical utility of next-generation sequencing (NGS) in treating high-grade serous ovarian cancer (HGSC) with targeted therapies other than Poly (ADP-ribose) polymerase (PARP) inhibitors. The search was performed in PubMed and Embase. The literature search combined screening the reference sections of relevant studies. A total of 1882 studies were screened, and 6 case reports met the inclusion criteria. The patients were treated with trametinib, crizotinib, alectinib, a protein kinase B (AKT) inhibitor, everolimus-letrozole or trastuzumab-pertuzumab. A partial response was observed in patients (n = 3) treated with trametinib, crizotinib or trastuzumab-pertuzumab. One patient treated with alectinib had a complete response, while the patients (n = 2) treated with AKT inhibitor or everolimus-letrozole had stable disease and progressive disease. The results suggest that NGS may have a role in identifying effective targeted therapies for patients diagnosed with HGSC. Further research, including basket trials, is needed to confirm the results.

Ovarian neoplasm; Ovarian epithelial cancer; Genetic testing; Precision medicine; Target therapy

[1] Lheureux S, Gourley C, Vergote I, Oza AM. Epithelial ovarian cancer. The Lancet. 2019; 393: 1240–1253.

[2] Webb PM, Jordan SJ. Global epidemiology of epithelial ovarian cancer. Nature Reviews Clinical Oncology. 2024; 21: 389–400.

[3] Konstantinopoulos PA, Matulonis UA. Clinical and translational advances in ovarian cancer therapy. Nature Cancer. 2023; 4: 1239–1257.

[4] Ledermann JA, Raja FA, Fotopoulou C, Gonzalez-Martin A, Colombo N, Sessa C; ESMO Guidelines Working Group. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology. 2013; 24: vi24–vi32.

[5] Sambasivan S. Epithelial ovarian cancer: review article. Cancer Treatment and Research Communications. 2022; 33: 100629.

[6] Armstrong DK, Alvarez RD, Backes FJ, Bakkum-Gamez JN, Barroilhet L, Behbakht K, et al. NCCN Guidelines® Insights: ovarian cancer, version 3. 2022. Journal of the National Comprehensive Cancer Network. 2022; 20: 972–980.

[7] Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature. 2011; 474: 609–615.

[8] Sisman Y, Vestergaard LK, de Oliveira DNP, Poulsen TS, Schnack TH, Høgdall C, et al. Potential targeted therapies in ovarian cancer. Pharmaceuticals. 2022; 15: 1324.

[9] Liu J, Berchuck A, Backes FJ, Cohen J, Grisham R, Leath CA, et al. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Ovarian cancer including fallopian tube cancer and primary peritoneal cancer, version 3. 2024. Available at: https://www.nccn.org/professionals/physician_gls/pdf/ovarian.pdf (Accessed: 15 January 2025).

[10] Colombo N, Ledermann JA; ESMO Guidelines Committee. Updated treatment recommendations for newly diagnosed epithelial ovarian carcinoma from the ESMO Clinical Practice Guidelines. Annals of Oncology. 2021; 32: 1300–1303.

[11] Armstrong DK. New therapies for ovarian cancer. Journal of the National Comprehensive Cancer Network. 2018; 16: 632–635.

[12] Wang H, Guo M, Wei H, Chen Y. Targeting p53 pathways: mechanisms, structures, and advances in therapy. Signal Transduction and Targeted Therapy. 2023; 8: 92.

[13] Vestergaard LK, Oliveira DNP, Høgdall CK, Høgdall EV. Next generation sequencing technology in the clinic and its challenges. Cancers. 2021; 13: 1751.

[14] Wessman S, Fuentes BB, Törngren T, Kvist A, Kokaraki G, Menkens H, et al. Precision oncology of high-grade ovarian cancer defined through targeted sequencing. Cancers. 2021; 13: 5240.

[15] Harbin LM, Gallion HH, Allison DB, Kolesar JM. Next generation sequencing and molecular biomarkers in ovarian cancer—an opportunity for targeted therapy. Diagnostics. 2022; 12: 842.

[16] Zhou Y, Tao L, Qiu J, Xu J, Yang X, Zhang Y, et al. Tumor biomarkers for diagnosis, prognosis and targeted therapy. Signal Transduction and Targeted Therapy. 2024; 9: 132.

[17] Hu T, Chitnis N, Monos D, Dinh A. Next-generation sequencing technologies: an overview. Human Immunology. 2021; 82: 801–811.

[18] Targeted Agent & Profiling Utilization Registry (TAPUR) Study. 2024. Available at: https://www.asco.org/research-data/tapur-study (Accessed: 22 May 2024).

[19] American Society of Clinical Oncology. ComboMATCH Precision Medicine Clinical Trials. 2024. Available at: https://www.cancer.gov/research/infrastructure/clinical-trials/nci-supported/combomatch (Accessed: 22 May 2024).

[20] Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. The BMJ. 2021; 372: n71.

[21] Cappuccio S, Distefano MG, Ghizzoni V, Fagotti A, Scambia G. Trametinib response in heavily pretreated high-grade ovarian cancer: one step towards precision medicine. Gynecologic Oncology Reports. 2020; 32: 100547.

[22] Dong D, Shen G, Da Y, Zhou M, Yang G, Yuan M, et al. Successful treatment of patients with refractory high-grade serous ovarian cancer with GOPC-ROS1 fusion using crizotinib: a case report. Oncologist. 2020; 25: e1720–e1724.

[23] Hui B, Zhang J, Shi X, Xing F, Shao YW, Wang Y, et al. EML4-ALK, a potential therapeutic target that responds to alectinib in ovarian cancer. Japanese Journal of Clinical Oncology. 2020; 50: 1470–1474.

[24] Lee YJ, Kim D, Kim HS, Na K, Lee JY, Nam EJ, et al. Integrating a next generation sequencing panel into clinical practice in ovarian cancer. Yonsei Medical Journal. 2019; 60: 914–923.

[25] Sawada K, Nakayama K, Nakamura K, Yoshimura Y, Razia S, Ishikawa M, et al. Clinical outcomes of genotype-matched therapy for recurrent gynecological cancers: a single institutional experience. Healthcare. 2021; 9: 1395.

[26] Thouvenin L, Charrier M, Clement S, Christinat Y, Tille JC, Frigeri M, et al. Ovarian cancer with high-level focal ERBB2 amplification responds to trastuzumab and pertuzumab. Gynecologic Oncology Reports. 2021; 37: 100787.

[27] Gershenson DM, Miller A, Brady WE, Paul J, Carty K, Rodgers W, et al. Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial. The Lancet. 2022; 399: 541–553.

[28] Camidge DR, Dziadziuszko R, Peters S, Mok T, Noe J, Nowicka M, et al. Updated efficacy and safety data and impact of the EML4-ALK fusion variant on the efficacy of alectinib in untreated ALK-positive advanced non-small cell lung cancer in the global phase III ALEX study. Journal of Thoracic Oncology. 2019; 14: 1233–1243.

[29] Altomare DA, Testa JR. Perturbations of the AKT signaling pathway in human cancer. Oncogene. 2005; 24: 7455–7464.

[30] Forbes SA, Beare D, Boutselakis H, Bamford S, Bindal N, Tate J, et al. COSMIC: somatic cancer genetics at high-resolution. Nucleic Acids Research. 2017; 45: D777–D783.

[31] Slomovitz BM, Filiaci VL, Walker JL, Taub MC, Finkelstein KA, Moroney JW, et al. A randomized phase II trial of everolimus and letrozole or hormonal therapy in women with advanced, persistent or recurrent endometrial carcinoma: a GOG Foundation study. Gynecologic Oncology. 2022; 164: 481–491.

[32] Kunte S, Abraham J, Montero AJ. Novel HER2-targeted therapies for HER2-positive metastatic breast cancer. Cancer. 2020; 126: 4278–4288.

[33] Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). European Journal of Cancer. 2009; 45: 228–247.

[34] Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al; ACMG Laboratory Quality Assurance Committee. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genetics in Medicine. 2015; 17: 405–424.

[35] Rodon J, Soria JC, Berger R, Miller WH, Rubin E, Kugel A, et al. Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial. Nature Medicine. 2019; 25: 751–758.

[36] Hobbs BP, Pestana RC, Zabor EC, Kaizer AM, Hong DS. Basket trials: review of current practice and innovations for future trials. Journal of Clinical Oncology. 2022; 40: 3520–3528.

[37] Murciano-Goroff YR, Uppal M, Chen M, Harada G, Schram AM. Basket trials: past, present, and future. Annual Review of Cancer Biology. 2024; 8: 59–80.

[38] Flaherty KT, Gray RJ, Chen AP, Li S, Mcshane LM, Patton D, et al. Molecular landscape and actionable alterations in a genomically guided cancer clinical trial: national cancer institute molecular analysis for therapy choice (NCI-MATCH). Journal of Clinical Oncology. 2020; 38: 3883–3894.

[39] Jardim DL, Schwaederle M, Wei C, Lee JJ, Hong DS, Eggermont AM, et al. Impact of a biomarker-based strategy on oncology drug development: a meta-analysis of clinical trials leading to FDA approval. Journal of the National Cancer Institute. 2015; 107: djv253.

[40] Schwaederle M, Zhao M, Lee JJ, Lazar V, Leyland-Jones B, Schilsky RL, et al. Association of biomarker-based treatment strategies with response rates and progression-free survival in refractory malignant neoplasms: a meta-analysis. JAMA Oncology. 2016; 2: 1452–1459.

[41] Schwaederle M, Zhao M, Lee JJ, Eggermont AM, Schilsky RL, Mendelsohn J, et al. Impact of precision medicine in diverse cancers: a meta-analysis of phase ii clinical trials. Journal of Clinical Oncology. 2015; 33: 3817–3825.

[42] Giudice E, Huang TT, Nair JR, Zurcher G, McCoy A, Nousome D, et al. The CHK1 inhibitor prexasertib in BRCA wild-type platinum-resistant recurrent high-grade serous ovarian carcinoma: a phase 2 trial. Nature Communications. 2024; 15: 2805.

[43] Konstantinopoulos PA, Lacchetti C, Annunziata CM. Germline and somatic tumor testing in epithelial ovarian cancer: ASCO guideline summary. JCO Oncology Practice. 2020; 16: e835–e838.

[44] Yin Y, Butler C, Zhang Q. Challenges in the application of NGS in the clinical laboratory. Human Immunology. 2021; 82: 812–819.

[45] Larson NB, Oberg AL, Adjei AA, Wang L. A clinician’s guide to bioinformatics for next-generation sequencing. Journal of Thoracic Oncology. 2023; 18: 143–157.

[46] Schmid S, Jochum W, Padberg B, Demmer I, Mertz KD, Joerger M, et al. How to read a next-generation sequencing report—what oncologists need to know. ESMO Open. 2022; 7: 100570.

[47] Larson KL, Huang B, Weiss HL, Hull P, Westgate PM, Miller RW, et al. Clinical outcomes of molecular tumor boards: a systematic review. JCO Precision Oncology. 2021; 5: PO.20.00495.

[48] Huang B, Chen Q, Allison D, El Khouli R, Peh KH, Mobley J, et al. Molecular tumor board review and improved overall survival in non-small-cell lung cancer. JCO Precision Oncology. 2021; 5: PO.21.00210.

[49] Tsimberidou AM, Kahle M, Vo HH, Baysal MA, Johnson A, Meric-Bernstam F. Molecular tumour boards—current and future considerations for precision oncology. Nature Reviews Clinical Oncology. 2023; 20: 843–863.

[50] Lambert JM, Gorzov P, Veprintsev DB, Söderqvist M, Segerbäck D, Bergman J, et al. PRIMA-1 reactivates mutant p53 by covalent binding to the core domain. Cancer Cell. 2009; 15: 376–388.

[51] Mohell N, Alfredsson J, Fransson Å, Uustalu M, Byström S, Gullbo J, et al. APR-246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cells. Cell Death & Disease. 2015; 6: e1794.

[52] Nissen T, Wynn R. The clinical case report: a review of its merits and limitations. BMC Research Notes. 2014; 7: 264.

[53] Kasim A, Bean N, Hendriksen SJ, Chen TT, Zhou H, Psioda MA. Basket trials in oncology: a systematic review of practices and methods, comparative analysis of innovative methods, and an appraisal of a missed opportunity. Frontiers in Oncology. 2023; 13: 1266286.

[54] Fountzilas E, Tsimberidou AM, Vo HH, Kurzrock R. Clinical trial design in the era of precision medicine. Genome Medicine. 2022; 14: 101.

[55] Easterbrook PJ, Berlin JA, Gopalan R, Matthews DR. Publication bias in clinical research. The Lancet. 1991; 337: 867–872.